Fei Huang
Bristol-Myers Squibb Company
Princeton
NJ 08543
USA
Name/email consistency: high
- The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Huang, F., Greer, A., Hurlburt, W., Han, X., Hafezi, R., Wittenberg, G.M., Reeves, K., Chen, J., Robinson, D., Li, A., Lee, F.Y., Gottardis, M.M., Clark, E., Helman, L., Attar, R.M., Dongre, A., Carboni, J.M. Cancer Res. (2009)
- Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T.W., Lee, F., Shaw, P., Clark, E. Cancer Res. (2007)